P Patrick Basu1, Niraj J Shah2, Nimy John3, Mark M Aloysius4, Ked Fortuzi5. 1Columbia Presbyterian Hospital, New York, 2University of Mississippi Medical Center, 3St. Vincents Hospital, Worcester, MA, 4James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, NY, 5King’s County Hospital Medical Center, NY
Background: CHC is no longer a clinical challenge in the era of DAA’s. CHC and SCD contributes added challenges (sickle cell hepatopathy, splenic dysfunction, accelerated fibrosis secondary to anemia, iron overload and LPS induced mitochondrial injury). Historical management with IFN and RBV causes fatal hemolysis, severe anemia and sepsis.
Aim:This study evaluates the safety, efficacy and eradication of hepatitis C in this sub-group population with SCD
Methods: 24 patients were recruited from three sickle cell centers in NYC.
Inclusion criteria: CHC (Geno specific with variation, diagnosed between 1998-2014) with SCD in remission (with sickle cell history > 30 years)
All patients were placed LDV 90 mg + SOF 400 mg a day; with food for 12 weeks
|undetectable||LDV 90 mg and SOF 400 mg|
|Day 7, n, %||9/24|
|Day 14, n, %||14/24|
|Day 30, n, %||22/24|
|Day 60, n , %||22/24|
|Day 90, EOT, , n, %||22/24|
|Population Viral failure- 1a/4c & 1a/3c||8.3% (2/24)|
|Pre and post RAV||1/24 (G 1a/4c)|
Conclusion: This study demonstrates that LDV and SOF combination in SCD patients with CHC is safe and well tolerated; with an SVR12 of 91.67% (22/24) with 8.3% (2/24) viral failure (in concomitant genotypes; 1a/4c and 1a/3c).
Presented at the SAGES 2017 Annual Meeting in Houston, TX.
Abstract ID: 80567
Program Number: P449
Presentation Session: Poster (Non CME)
Presentation Type: Poster